AstraZeneca has announced plans to build a $1.5-billion manufacturing facility in Singapore for antibody drug conjugates (ADCs). 

The planned greenfield facility, supported by the Singapore Economic Development Board will be AstraZeneca’s first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale.  

AstraZeneca will work with Singapore’s government and other partners on green solutions for the ADC facility. This facility will be designed to emit zero carbon from its first day of operations. 

AstraZeneca aims to begin design and construction of the manufacturing facility by the end of 2024, with targeted operational readiness from 2029. 

Source: AstraZeneca